Sym-011

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameSym-011
Drug Alias NameDimerceptHermodulinsRBLX-242hherstatinRBLX-642h +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsReceptor protein-tyrosine kinase erbB-4 antagonistsEpidermal growth factor receptor erbB1 antagonists +[5] 
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2Receptor protein-tyrosine kinase erbB-4 +[4] 
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesDenmark
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesReceptor BioLogix Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesReceptor BioLogix IncSymphogen A/S
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A